These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 11728181)

  • 1. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis.
    Bramson HN; Corona J; Davis ST; Dickerson SH; Edelstein M; Frye SV; Gampe RT; Harris PA; Hassell A; Holmes WD; Hunter RN; Lackey KE; Lovejoy B; Luzzio MJ; Montana V; Rocque WJ; Rusnak D; Shewchuk L; Veal JM; Walker DH; Kuyper LF
    J Med Chem; 2001 Dec; 44(25):4339-58. PubMed ID: 11728181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities.
    Kim KS; Kimball SD; Misra RN; Rawlins DB; Hunt JT; Xiao HY; Lu S; Qian L; Han WC; Shan W; Mitt T; Cai ZW; Poss MA; Zhu H; Sack JS; Tokarski JS; Chang CY; Pavletich N; Kamath A; Humphreys WG; Marathe P; Bursuker I; Kellar KA; Roongta U; Batorsky R; Mulheron JG; Bol D; Fairchild CR; Lee FY; Webster KR
    J Med Chem; 2002 Aug; 45(18):3905-27. PubMed ID: 12190313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
    Arris CE; Boyle FT; Calvert AH; Curtin NJ; Endicott JA; Garman EF; Gibson AE; Golding BT; Grant S; Griffin RJ; Jewsbury P; Johnson LN; Lawrie AM; Newell DR; Noble ME; Sausville EA; Schultz R; Yu W
    J Med Chem; 2000 Jul; 43(15):2797-804. PubMed ID: 10956187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives.
    Gibson AE; Arris CE; Bentley J; Boyle FT; Curtin NJ; Davies TG; Endicott JA; Golding BT; Grant S; Griffin RJ; Jewsbury P; Johnson LN; Mesguiche V; Newell DR; Noble ME; Tucker JA; Whitfield HJ
    J Med Chem; 2002 Aug; 45(16):3381-93. PubMed ID: 12139449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2.
    Mesguiche V; Parsons RJ; Arris CE; Bentley J; Boyle FT; Curtin NJ; Davies TG; Endicott JA; Gibson AE; Golding BT; Griffin RJ; Jewsbury P; Johnson LN; Newell DR; Noble ME; Wang LZ; Hardcastle IR
    Bioorg Med Chem Lett; 2003 Jan; 13(2):217-22. PubMed ID: 12482427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. X-ray crystallographic studies of CDK2, a basis for cyclin-dependent kinase inhibitor design in anti-cancer drug research.
    Furet P
    Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):15-23. PubMed ID: 12678911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The design and synthesis of purine inhibitors of CDK2. III.
    Shum PW; Peet NP; Weintraub PM; Le TB; Zhao Z; Barbone F; Cashman B; Tsay J; Dwyer S; Loos PC; Powers EA; Kropp K; Wright PS; Bitonti A; Dumont J; Borcherding DR
    Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):1067-78. PubMed ID: 11562960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3(1,2).
    Yue EW; Higley CA; DiMeo SV; Carini DJ; Nugiel DA; Benware C; Benfield PA; Burton CR; Cox S; Grafstrom RH; Sharp DM; Sisk LM; Boylan JF; Muckelbauer JK; Smallwood AM; Chen H; Chang CH; Seitz SP; Trainor GL
    J Med Chem; 2002 Nov; 45(24):5233-48. PubMed ID: 12431051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of potent oxindole CDK2 inhibitors.
    Dermatakis A; Luk KC; DePinto W
    Bioorg Med Chem; 2003 Apr; 11(8):1873-81. PubMed ID: 12659774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects.
    Kim KS; Sack JS; Tokarski JS; Qian L; Chao ST; Leith L; Kelly YF; Misra RN; Hunt JT; Kimball SD; Humphreys WG; Wautlet BS; Mulheron JG; Webster KR
    J Med Chem; 2000 Nov; 43(22):4126-34. PubMed ID: 11063609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors.
    Davis ST; Benson BG; Bramson HN; Chapman DE; Dickerson SH; Dold KM; Eberwein DJ; Edelstein M; Frye SV; Gampe RT; Griffin RJ; Harris PA; Hassell AM; Holmes WD; Hunter RN; Knick VB; Lackey K; Lovejoy B; Luzzio MJ; Murray D; Parker P; Rocque WJ; Shewchuk L; Veal JM; Walker DH; Kuyper LF
    Science; 2001 Jan; 291(5501):134-7. PubMed ID: 11141566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Cdk2 activation by selected tyrphostins causes cell cycle arrest at late G1 and S phase.
    Kleinberger-Doron N; Shelah N; Capone R; Gazit A; Levitzki A
    Exp Cell Res; 1998 Jun; 241(2):340-51. PubMed ID: 9637776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of cylin-dependent kinase 1 inhibitors of a new chemical type by structure-based design and database searching.
    Furet P; Meyer T; Mittl P; Fretz H
    J Comput Aided Mol Des; 2001 May; 15(5):489-95. PubMed ID: 11394741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases.
    Misra RN; Rawlins DB; Xiao HY; Shan W; Bursuker I; Kellar KA; Mulheron JG; Sack JS; Tokarski JS; Kimball SD; Webster KR
    Bioorg Med Chem Lett; 2003 Mar; 13(6):1133-6. PubMed ID: 12643928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
    Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L
    J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
    Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
    Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological activities of C-2, N-9 substituted 6-benzylaminopurine derivatives as cyclin-dependent kinase inhibitor.
    Oh CH; Lee SC; Lee KS; Woo ER; Hong CY; Yang BS; Baek DJ; Cho JH
    Arch Pharm (Weinheim); 1999 Jun; 332(6):187-90. PubMed ID: 10399486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
    Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
    Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
    David-Pfeuty T
    Oncogene; 1999 Dec; 18(52):7409-22. PubMed ID: 10602500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors.
    Zhu G; Conner SE; Zhou X; Shih C; Li T; Anderson BD; Brooks HB; Campbell RM; Considine E; Dempsey JA; Faul MM; Ogg C; Patel B; Schultz RM; Spencer CD; Teicher B; Watkins SA
    J Med Chem; 2003 May; 46(11):2027-30. PubMed ID: 12747775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.